ArticleJournal of neuro-oncology2023

First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial.

Matthew Holdaway et al.PubMed ↗Publisher ↗

No numbers read from the abstract.